menu
    • menu
    [{"orgOrder":0,"company":"Polarean","sponsor":"Aerogen","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Salbutamol Sulphate","moa":"Beta-2 adrenergic receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Polarean","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Polarean \/ Aerogen","highestDevelopmentStatusID":"6","companyTruncated":"Polarean \/ Aerogen"},{"orgOrder":0,"company":"Polarean","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Radiolabeled Compound","year":"2018","type":"Inapplicable","leadProduct":"129Xe MRI","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase III","graph3":"Polarean","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Polarean \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Polarean \/ Undisclosed"},{"orgOrder":0,"company":"Polarean","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Radiolabeled Compound","year":"2018","type":"Inapplicable","leadProduct":"129Xe MRI","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase III","graph3":"Polarean","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Polarean \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Polarean \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Polarean

    Menu

    Polarean

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Polarean

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Polarean

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Salbutamol Sulphate

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase I

                            Sponsor : Aerogen

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Comparison of Bronchodilator Response From Three Different Aerosol Delivery Methods in Patients With COPD Usin...

                            Details : Albuterol Sulfate is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Pulmonary Disease, Chronic Obstructive.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 21, 2024

                            Lead Product(s) : Salbutamol Sulphate

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase I

                            Sponsor : Aerogen

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Polarean

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Polarean

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 129Xe MRI

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Hyperpolarized Xenon MRI for Assessment of Pulmonary Function in Lung Transplant

                            Details : 129Xe MRI is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            February 01, 2018

                            Lead Product(s) : 129Xe MRI

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Polarean

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Polarean

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 129Xe MRI

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Hyperpolarized Xenon MRI for Assessment of Pulmonary Function in Lung Resection

                            Details : 129Xe MRI is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            January 31, 2018

                            Lead Product(s) : 129Xe MRI

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth